Abby Statler, PhD, MPH, discusses findings from an analysis of common clinical trial exclusion criteria and outcomes in clinical trials, which suggest that eligibility criteria should be “liberalized.”
Recent Articles
Lawmakers Call for Investigation Into Federal Contributions to Remdesivir Development
A letter penned by Senator Debbie Stabenow (D-MI), of the Senate Committee on Oversight and Reform, and Representative Carolyn Maloney (D-NY), who chairs the...
Advocacy Groups Petition FDA to Limit Music During Drug Ads
Two advocacy groups, Knowledge Ecology International and the Center for Digital Democracy, filed a citizen’s petition with the FDA regarding the use of music...
FDA Grants Accelerated Approval to Tafasitamab-cxix for Relapsed/Refractory DLBCL
The FDA has granted accelerated approval to tafasitamab-cxix in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell...
NIH Awards $249 Million to Seven Companies for COVID-19 Diagnostic Development
The National Institutes of Health (NIH) has awarded $249 million in grants to seven medical diagnostic companies making new coronavirus diagnostic technology, in hopes...
How Well Do Antibody Tests Detect Mild COVID-19 Infection?
An Oxford University study of more than 9,000 health-care workers suggests antibody tests are not effective for people who had only a mild COVID-19...
Current Issue
August 2020 Volume 6, Issue 10
This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.